Upgrade Alert for Eli Lilly (LLY)
Eli Lilly (NYSE:LLY) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $79.89 on volume of 4.4 million shares, above average daily volume of 3.5 million.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company's products are sold in countries around the world. Eli Lilly's products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
In the past 52 weeks, shares of Eli Lilly have traded between a low of $67.88 and a high of $92.85 and closed yesterday at $79.89, which is 18% above that low price. The 200-day and 50-day moving averages have moved 0.28% lower and 0.27% higher over the past week, respectively.
Eli Lilly (NYSE:LLY) has potential upside of 23.2% based on a current price of $79.89 and analysts' consensus price target of $98.39. The stock should hit resistance at its 200-day moving average (MA) of $80.00, as well as support at its 50-day MA of $74.01.
SmarTrend is tracking the current trend status for Eli Lilly and will alert subscribers who have LLY in their portfolio or watchlist when shares have changed trend direction.
Keywords: analyst upgrades/downgrades Eli Lilly